ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors

Recruiting

Phase 1

ONC206ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors

Sponsor:

Sabine Mueller, MD, PhD

Code:

NCT04732065

Conditions

Diffuse Midline Glioma (DMG)

Glioblastoma

Recurrent Ependymoma

Recurrent Malignant Central Nervous System Neoplasm

Spinal Cord Glioma

Eligibility Criteria

Sex: All

Age: 2 - 21

Healthy Volunteers: Not accepted

Interventions

ONC206

Standard of Care Radiation Therapy

Optional Proton (1H) MR spectroscopy (MRS)

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-25. This information was provided to ClinicalTrials.gov by Sabine Mueller, MD, PhD on 2024-12-11.